Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34493
Abstract: At an interim analysis (median follow‐up, 6.2 months; n = 187), the phase 3 COSMIC‐311 trial met the primary end point of progression‐free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs.… read more here.
Keywords: previously treated; cosmic 311; treated radioiodine; 311 trial ... See more keywords